Safety Profile
Information not yet available for this ingredient profile.
Interactions
Information not yet available for this ingredient profile.
Evidence and Scientific Findings
Ingredient Overview
Coral calcium is calcium derived from fossilised coral limestone, often providing calcium with trace magnesium and trace minerals. Despite marketing claims, clinical evidence does not support superiority over standard calcium carbonate or citrate. Safety profile is equivalent to other calcium supplements at recommended doses. Excessive calcium intake (>2,500 mg/day total) increases risk of hypercalcaemia, kidney stones, and cardiovascular calcification. Harvesting from living coral reefs raises environmental and regulatory concerns; choose certified fossilised sources.
Biological and Chemical Classification
Information not yet available for this ingredient profile.
Mechanism of Action
Information not yet available for this ingredient profile.
Clinical Evidence of Effectiveness
Information not yet available for this ingredient profile.
Pharmacokinetics
Information not yet available for this ingredient profile.
Recommended Dosage
Information not yet available for this ingredient profile.
SETI — Scientific Evidence Transparency Index
Executive Summary — Ingredient Assessment
- 10 studies reviewed
- 0 high-quality studies (meta-analysis or RCT)
- Main clinical benefit observed: Minerals
- Evidence consistency: High consistency across studies (100%)
- No significant safety signals identified in the reviewed literature.
The available scientific evidence for Coral Calcium indicates notable safety signals that warrant caution. Use should be considered carefully and monitored, particularly in sensitive populations or alongside other medications.
Total SETI Score
High risk| Evidence quality | 10/40 |
| Evidence consistency | 20/20 |
| Safety signals | 0/20 |
| Study recency | 10/10 |
| Evidence transparency | 10/10 |
Evidence Summary
- 10 studies reviewed
- 0 high-quality studies (meta-analysis or systematic review)
- 0 studies identified benefits or no safety concern (GREEN)
- 10 studies reported limited or advisory safety evidence (YELLOW)
Evidence Policy
Only peer-reviewed scientific literature indexed in PubMed or comparable databases is included in this evaluation. Commercial websites, blogs, and marketing materials are excluded. All references include direct traceable links to source documents.
Last updated: 06 აპრ 2026, 12:09
Evidence Distribution
-
Observational / other LOW evidence YELLOWComparative Efficacy of Coral Calcium Carried Hydrogen versus Dexamethasone in a Mouse Model of Allergic Contact Dermatitis. ↗Huang G et al.. Comparative Efficacy of Coral Calcium Carried Hydrogen versus Dexamethasone in a Mouse Model of Allergic Contact Dermatitis.. J Inflamm Res. 2026. PMID:41709966.PMID 41709966 ↗Journal J Inflamm ResYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41709966/
-
Observational / other LOW evidence YELLOWHydrogen intervention attenuates chronic hypoxia-induced bone degeneration and multi-organ damage via modulation of the gut microbiota. ↗Zhu S et al.. Hydrogen intervention attenuates chronic hypoxia-induced bone degeneration and multi-organ damage via modulation of the gut microbiota.. Bone. 2026. PMID:41224067.PMID 41224067 ↗Journal BoneYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41224067/
-
Observational / other LOW evidence YELLOWThe Gastroprotective Effect of Hydrogen-Rich Coral Calcium in a Mouse Model of Peptic Ulcer Disease. ↗Wu HT et al.. The Gastroprotective Effect of Hydrogen-Rich Coral Calcium in a Mouse Model of Peptic Ulcer Disease.. Drug Des Devel Ther. 2025. PMID:41221497.PMID 41221497 ↗Journal Drug Des Devel TherYear 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41221497/
-
Observational / other LOW evidence YELLOWPredicting Therapeutic Response to Molecular Hydrogen in Autoimmune Diseases via Immunophenotyping. ↗Lui SW et al.. Predicting Therapeutic Response to Molecular Hydrogen in Autoimmune Diseases via Immunophenotyping.. APMIS. 2025. PMID:40590161.PMID 40590161 ↗Journal APMISYear 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/40590161/
-
Observational / other LOW evidence YELLOWCoral calcium hydride promotes peripheral mitochondrial division and reduces AT-II cells damage in ARDS via activation of the Trx2/Myo19/Drp1 pathway. ↗Li Q et al.. Coral calcium hydride promotes peripheral mitochondrial division and reduces AT-II cells damage in ARDS via activation of the Trx2/Myo19/Drp1 pathway.. J Pharm Anal. 2025. PMID:40177064.PMID 40177064 ↗Journal J Pharm AnalYear 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/40177064/
-
Observational / other LOW evidence YELLOWA Novel Antioxidant, Hydrogen-Rich Coral Calcium Alters Gut Microbiome and Bile Acid Synthesis to Improve Methionine-and-Choline-Deficient Diet-Induced Non-Alcoholic Fatty Liver Disease. ↗Wu HT et al.. A Novel Antioxidant, Hydrogen-Rich Coral Calcium Alters Gut Microbiome and Bile Acid Synthesis to Improve Methionine-and-Choline-Deficient Diet-Induced Non-Alcoholic Fatty Liver Disease.. Antioxidants (Basel). 2024. PMID:38929185.PMID 38929185 ↗Journal Antioxidants (Basel)Year 2024Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/38929185/
-
Observational / other LOW evidence YELLOWEvaluation of the safety and potential lipid-lowering effects of oral hydrogen-rich coral calcium (HRCC) capsules in patients with metabolic syndrome: a prospective… ↗Chiu SH et al.. Evaluation of the safety and potential lipid-lowering effects of oral hydrogen-rich coral calcium (HRCC) capsules in patients with metabolic syndrome: a prospective case series study.. Front Nutr. 2023. PMID:37521410.PMID 37521410 ↗Journal Front NutrYear 2023Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/37521410/
-
Observational / other LOW evidence YELLOWCoral calcium carried hydrogen ameliorates the severity of non-alcoholic steatohepatitis induced by a choline deficient high carbohydrate fat-free diet in elderly rats. ↗Ma K et al.. Coral calcium carried hydrogen ameliorates the severity of non-alcoholic steatohepatitis induced by a choline deficient high carbohydrate fat-free diet in elderly rats.. Sci Rep. 2023. PMID:37468618.PMID 37468618 ↗Journal Sci RepYear 2023Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/37468618/
-
Observational / other LOW evidence YELLOWThe Role of Hyperthermia in Methamphetamine-Induced Depression-Like Behaviors: Protective Effects of Coral Calcium Hydride. ↗Wang X et al.. The Role of Hyperthermia in Methamphetamine-Induced Depression-Like Behaviors: Protective Effects of Coral Calcium Hydride.. Front Mol Neurosci. 2021. PMID:35058751.PMID 35058751 ↗Journal Front Mol NeurosciYear 2021Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/35058751/
-
Observational / other LOW evidence YELLOWProtonography and anion inhibition profile of the u03b1-carbonic anhydrase (CruCA4) identified in the Mediterranean red coral Corallium rubrum. ↗Del Prete S et al.. Protonography and anion inhibition profile of the u03b1-carbonic anhydrase (CruCA4) identified in the Mediterranean red coral Corallium rubrum.. Bioorg Chem. 2018. PMID:29223031.PMID 29223031 ↗Journal Bioorg ChemYear 2018Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/29223031/
Score Transparency
0 of 10 approved references (score saturates at 10). More peer-reviewed studies = stronger evidence base.
Method: Q = number of approved references ÷ 10 (capped at 1.0)
Limited — mostly case reports or animal studies
Method: L = mean study-level weight across approved references. Level 1 (meta-analysis / systematic review) = 1.0; Level 2 (RCT) = 0.8; Level 3 (cohort/case-control) = 0.6; Level 4 (case report) = 0.4; Level 5 (animal / in-vitro) = 0.2.
Mixed or neutral — roughly equal benefit and risk signals
Method: D = (sum of risk-scored references − sum of benefit-scored references) ÷ total evidence score, then scaled from [−1, 1] to [0, 1]. 0.0 = pure benefit; 0.5 = neutral; 1.0 = pure risk.
One or more monitoring-level safety signals active
Method: S = 0.5 (neutral baseline) + sum of active signal severity deltas ÷ 10. Severity deltas: Critical = +2.0, High = +1.5, Moderate = +1.0, Low = +0.5. Capped at 1.0.
Final GIRI Score for Coral Calcium. Risk level thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.
Full methodology & data sources
The GIRI Score is computed entirely from structured data — no editorial scoring or subjective weighting is applied at any step.
- References: Only approved references are counted. Each reference is assigned an evidence level (L1–L5) and a direction (risk / neutral / benefit) by the reference manager or AI classifier.
- Safety Signals: Sourced from regulatory agencies (FDA, EMA, Health Canada, TGA, and others) and pharmacovigilance databases. Only active signals count toward the score.
- Formula version: GIRI Score v3.7.0 — Q × L × D × S × 10.
- Limitations: The score reflects published evidence and recorded signals as of the last update date. It is not a clinical risk assessment and should not replace advice from a qualified healthcare professional.
Risk Level Classification
Based on available regulatory signals and scientific evidence, this ingredient presents a low safety concern under normal conditions of use.
0–3.0
3.0–5.5
5.5–7.5
7.5–10
The score pin shows exactly where this ingredient falls on the fixed risk scale.
What drove the Low classification for Coral Calcium
A score of 2.0 places this ingredient in the Low band. Thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.
0 approved references.
Limited — mostly case reports or animal studies (Level 4–5).
Neutral or mixed — benefit and risk signals roughly balanced.
No active signals — S component is at neutral baseline (0.5), contributing no extra risk weight.
No major regulatory restrictions or advisories recorded across monitored jurisdictions (FDA, EMA, Health Canada, TGA, and others).
How are the Low / Moderate / High / Critical thresholds defined?
The four risk levels are fixed score bands. A score is assigned to exactly one level based on where it falls:
| Level | Score | Meaning |
|---|---|---|
| LOW | 0.0 – 2.9 | Sparse or predominantly beneficial evidence. No active safety alerts. |
| MODERATE | 3.0 – 5.4 | Mixed signals — some risk alongside benefit. Caution at high doses or in sensitive groups. |
| HIGH | 5.5 – 7.4 | Multiple studies or regulatory alerts documenting adverse effects. Professional oversight recommended. |
| CRITICAL | 7.5 – 10 | Regulatory restrictions in one or more major jurisdictions. Serious documented harm. Avoid without specialist supervision. |
Thresholds are fixed constants (GIRI_Score_Utils::LEVEL_THRESHOLDS). They do not change per ingredient and are never subject to editorial adjustment.